What are Neurocrine Biosciences's profit margins?

Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.

Where do Neurocrine Biosciences's ratios come from?

Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Neurocrine Biosciences NBIX Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Gross margin	98.2%0.0pp	98.2%-0.2pp	98.4%-0.1pp	98.5%0.0pp	98.5%0.0pp
Operating margin	25.4%+3.8pp	21.6%+1.1pp	20.5%+0.8pp	19.7%-0.8pp	20.5%-3.7pp
Net margin	21.6%+4.8pp	16.7%+0.8pp	16%+2.1pp	13.9%+1.2pp	12.7%-1.8pp
EBITDA margin	26.4%+3.7pp	22.7%+1.1pp	21.6%+0.8pp	20.9%-0.8pp	21.7%-3.7pp
Free cash flow margin	26.8%+0.6pp	26.2%+4.1pp	22.1%+1.0pp	21.1%+0.7pp	20.4%-3.3pp
Returns
Return on equity	22.5%+6.1pp	16.4%+1.4pp	15%+1.6pp	13.4%+1.0pp	12.4%-1.7pp
Return on assets	15.6%+4.1pp	11.5%+0.5pp	11%+1.3pp	9.7%+1.1pp	8.5%-1.3pp
Return on invested capital	17.5%+3.2pp	14.4%+1.4pp	13%+1.2pp	11.8%-0.7pp	12.4%-2.7pp
Efficiency
Asset turnover	0.7×0.0×	0.7×0.0×	0.7×0.0×	0.7×0.0×	0.7×0.0×
Inventory turnover	0.9×+0.1×	0.8×+0.1×	0.8×0.0×	0.8×0.0×	0.7×+0.1×
Liquidity
Current ratio	2.9×-0.5×	3.4×0.0×	3.4×+0.2×	3.2×+0.1×	3.1×-0.3×
Quick ratio	2.9×-0.4×	3.3×0.0×	3.3×+0.2×	3.1×+0.1×	3×-0.3×
Cash ratio	0.3×-0.6×	1×+0.4×	0.5×0.0×	0.5×+0.1×	0.4×-0.1×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.2×0.0×	0.2×0.0×	0.2×0.0×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Net debt / EBITDA	0.2×+0.6×	-0.4×-0.6×	0.2×-0.2×	0.4×-0.1×	0.6×+0.1×
Per Share
Book value per share	$32.95+3.8%	$31.74+8.3%	$29.30+9.8%	$26.68+7.8%	$24.74-0.9%
Valuation
Market capitalization	$13.22B-6.5%	$14.14B+1.6%	$13.92B+9.8%	$12.69B+15.0%	$11.03B-20.2%
Enterprise value	$13.41B-3.5%	$13.89B-1.2%	$14.05B+8.9%	$12.9B+14.0%	$11.32B-19.6%
Price / earnings	19.8×-9.8×	29.5×-3.0×	32.5×-3.9×	36.4×+0.4×	36.1×-4.4×
Price / sales	4.3×-0.7×	4.9×-0.2×	5.2×+0.1×	5.1×+0.5×	4.6×-1.3×
Price / book	3.9×-0.5×	4.3×-0.3×	4.6×-0.1×	4.7×+0.4×	4.3×-1.0×
EV / EBITDA	16.4×-5.0×	21.4×-2.8×	24.2×-0.4×	24.6×+3.0×	21.6×-1.9×
EV / sales	4.3×-0.5×	4.9×-0.4×	5.2×+0.1×	5.1×+0.4×	4.7×-1.3×
Free cash flow yield	6.3%+1.0pp	5.3%+1.0pp	4.3%+0.1pp	4.2%-0.3pp	4.5%+0.4pp
Earnings yield	5.1%+1.7pp	3.4%+0.3pp	3.1%+0.3pp	2.7%0.0pp	2.8%+0.3pp
PEG ratio	0.2×-0.6×	0.7×-2.2×	3×-10.6×	13.6×—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Neurocrine Biosciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Neurocrine Biosciences's profit margins?: Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.
Where do Neurocrine Biosciences's ratios come from?: Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.